医学
乳腺癌
肺癌
放射治疗
肺
单变量分析
转移
前瞻性队列研究
肿瘤科
随机对照试验
癌症
放射外科
临床研究阶段
转移性乳腺癌
内科学
放射科
化疗
多元分析
作者
Davide Franceschini,Ciro Franzese,Tiziana Comito,Mariya Boyanova Ilieva,Ruggero Spoto,A.M. Marzo,Luca Dominici,Maria Massaro,Luisa Bellu,Marco Badalamenti,Pietro Mancosu,Marta Scorsetti
标识
DOI:10.1016/j.radonc.2024.110240
摘要
Abstract
Background and purpose
To report mature results for local control and survival in oligometastatic (OM) breast cancer patients treated with stereotactic body radiotherapy (SBRT) on lung and/or liver lesions in a phase II trial. Methods
This is a prospective non-randomized phase II trial (NCT02581670) which enrolled patients from 2015 to 2021. Eligibility criteria included: age > 18 years, ECOG 0–2, diagnosis of breast cancer, maximum of 4 lung/liver lesions (with a maximum diameter < 5 cm), metastatic disease confined to the lungs and liver or extrapulmonary or extrahepatic disease stable or responding to systemic therapy. The primary end-points were local control (LC) and treatment-related toxicities. The secondary end-points included overall survival (OS), distant metastasis-free survival (DMFS), time to next systemic therapy (TTNS), poly-progression free survival (PPFS). Results
The study included 64 patients with a total of 90 lesions treated with SBRT. LC at 1 and 2 years was 94.9 %, 91 % at 3 years. Median local control was not reached. Median OS was 16.5 months, OS at 1, 2 and 3 years was 87.5 %, 60.9 % and 51.9 %, respectively. Median DMFS was 8.3 months, DMFS at 1, 2 and 3 years was 38.1 %, 20.6 % and 16 % respectively. At univariate analysis, local response to SBRT was found to be statistically linked with better OS, DMFS and STFS. Conclusion
SBRT is a safe and valid option in oligometastatic breast cancer patients, with very high rates of local control. An optimal selection of patients is likely needed to improve survival outcomes and reduce the rate of distant progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI